

- 55) The composition according to claim 49, wherein said buffer is a citrate-phosphate buffer.
- 56) The composition according to claim 48, further comprising a bactericidal or bacteriostatic agent as a preservative.
- 57) The composition according to claim 48, wherein said lytic enzyme is lyophilized.
- 58) The composition according to claim 48, wherein said at least one lytic enzyme is present in a concentration of about 100 to about 100,000 active enzyme units per milliliter of fluid in the wet environment of the nasal or oral passages.
- 59) The composition according to claim 48, wherein said at least one lytic enzyme is present in a concentration of about 100 to about 10,000 active enzyme units per milliliter of fluid in the wet environment of the nasal or oral passages.


#### IN THE ABSTRACT

Please cancel the abstract and replace with the following:

- A lozenge for the treatment of *Streptococcus Group A* infections of the mouth, throat, and nasal passage is disclosed which comprises a lytic enzyme composition specific for *Streptococcus Group A* and a lozenge carrier for delivering the lytic enzyme.-

The application is now in condition for allowance. Please call the undersigned at (301) 603-9071 if you have any questions or comments. Thank you.

Very truly yours,

A handwritten signature in black ink, appearing to be "D. L. ...", written over the text "Very truly yours,".